These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 30515738

  • 1. Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms.
    Asada S, Kitamura T.
    Int J Hematol; 2019 Aug; 110(2):179-186. PubMed ID: 30515738
    [Abstract] [Full Text] [Related]

  • 2. ASXL1 mutation in clonal hematopoiesis.
    Fujino T, Kitamura T.
    Exp Hematol; 2020 Mar; 83():74-84. PubMed ID: 31945396
    [Abstract] [Full Text] [Related]

  • 3. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation.
    Nagase R, Inoue D, Pastore A, Fujino T, Hou HA, Yamasaki N, Goyama S, Saika M, Kanai A, Sera Y, Horikawa S, Ota Y, Asada S, Hayashi Y, Kawabata KC, Takeda R, Tien HF, Honda H, Abdel-Wahab O, Kitamura T.
    J Exp Med; 2018 Jun 04; 215(6):1729-1747. PubMed ID: 29643185
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Mutant ASXL1 cooperates with BAP1 to promote myeloid leukaemogenesis.
    Asada S, Goyama S, Inoue D, Shikata S, Takeda R, Fukushima T, Yonezawa T, Fujino T, Hayashi Y, Kawabata KC, Fukuyama T, Tanaka Y, Yokoyama A, Yamazaki S, Kozuka-Hata H, Oyama M, Kojima S, Kawazu M, Mano H, Kitamura T.
    Nat Commun; 2018 Jul 16; 9(1):2733. PubMed ID: 30013160
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.
    Bai J, Chen Z, Chen C, Zhang M, Zhang Y, Song J, Yuan J, Jiang X, Xing W, Yang J, Bai J, Zhou Y.
    Cancer Lett; 2021 Oct 28; 519():78-90. PubMed ID: 34186160
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epigenetic regulation by ASXL1 in myeloid malignancies.
    Yang FC, Agosto-Peña J.
    Int J Hematol; 2023 Jun 28; 117(6):791-806. PubMed ID: 37062051
    [Abstract] [Full Text] [Related]

  • 15. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression.
    Abdel-Wahab O, Adli M, LaFave LM, Gao J, Hricik T, Shih AH, Pandey S, Patel JP, Chung YR, Koche R, Perna F, Zhao X, Taylor JE, Park CY, Carroll M, Melnick A, Nimer SD, Jaffe JD, Aifantis I, Bernstein BE, Levine RL.
    Cancer Cell; 2012 Aug 14; 22(2):180-93. PubMed ID: 22897849
    [Abstract] [Full Text] [Related]

  • 16. Role of ASXL1 in hematopoiesis and myeloid diseases.
    Gao X, You X, Droin N, Banaszak LG, Churpek J, Padron E, Geissler K, Solary E, Patnaik MM, Zhang J.
    Exp Hematol; 2022 Nov 14; 115():14-19. PubMed ID: 36183966
    [Abstract] [Full Text] [Related]

  • 17. HHEX promotes myeloid transformation in cooperation with mutant ASXL1.
    Takeda R, Asada S, Park SJ, Yokoyama A, Becker HJ, Kanai A, Visconte V, Hershberger C, Hayashi Y, Yonezawa T, Tamura M, Fukushima T, Tanaka Y, Fukuyama T, Matsumoto A, Yamasaki S, Nakai K, Yamazaki S, Inaba T, Shibata T, Inoue D, Honda H, Goyama S, Maciejewski JP, Kitamura T.
    Blood; 2020 Oct 01; 136(14):1670-1684. PubMed ID: 32492700
    [Abstract] [Full Text] [Related]

  • 18. Epigenetic targeted therapy of stabilized BAP1 in ASXL1 gain-of-function mutated leukemia.
    Wang L, Birch NW, Zhao Z, Nestler CM, Kazmer A, Shilati A, Blake A, Ozark PA, Rendleman EJ, Zha D, Ryan CA, Morgan MAJ, Shilatifard A.
    Nat Cancer; 2021 May 01; 2(5):515-526. PubMed ID: 35122023
    [Abstract] [Full Text] [Related]

  • 19. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.
    Gelsi-Boyer V, Brecqueville M, Devillier R, Murati A, Mozziconacci MJ, Birnbaum D.
    J Hematol Oncol; 2012 Mar 21; 5():12. PubMed ID: 22436456
    [Abstract] [Full Text] [Related]

  • 20. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics.
    Abdel-Wahab O, Dey A.
    Leukemia; 2013 Jan 21; 27(1):10-5. PubMed ID: 23147254
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.